Suresh Satpati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suresh Satpati has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Kunal Rai
University of Texas MD Anderson Cancer Center
8 shared publications - Bing Z. Carter
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4 shared publications - Edward Ayoub
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4 shared publications - Guillermo Garcia-Manero
The University of Texas MD Anderson Cancer Center
4 shared publications - Ishtyaq Mahmud
University of Houston
4 shared publications - Jagan Mohan Reddy Dwarampudi
University of Houston
4 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Data from The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML
Purpose:Hypomethylating agent (HMA) and the BCL-2 inhibitor venetoclax (VEN) combinations have evolved into first-line therapies for patients with acute myeloid leukemia (AML), yielding high response rates. However, most patients ultimately relapse, particularly those with TP53 mutations. We investigated mechanisms of action and therapeutic efficacy of NTX-301, a next-generation HMA. Experimental Design:Methods used include flow cytometry–based cell viability assays, Western blotting, reverse-phase protein arrays, RNA sequencing, Cytometry by Time-Of-Flight single-cell mass cytometry, and methylation profiling in various therapy-resistant AML models. Results:We demonstrate that NTX-301 exhibits superior efficacy compared with 5-azacytidine (5-AZA) in 5-AZA– or VEN-resistant AML. It synergizes with VEN in VEN- or VEN/HMA-resistant and TP53-mutant AML blasts and stem/progenitor cells (combination index <1). NTX-301 inhibits DNA methyltransferase 1 (DNMT1) and increases p73 and caspase 8 (CASP8)/activated CASP8 levels in TP53 wild-type and TP53-mutant AML and activates p53 signaling. It extends survival (≥45%) in both xenograft and patient-derived xenograft models. Methylation profiling revealed that NTX-301 is a more targeted HMA compared with 5-AZA, enabling suppression of functionally enriched genes/pathways. Pathway analysis of 954 commonly hypomethylated genes showed profoundly greater enrichment of Hippo signaling in NTX-301–treated compared with 5-AZA–treated cells and enrichment of insulin signaling, VEGF pathway, and cell cycle selectively in NTX-301– but not in 5-AZA–treated cells. NTX-301–mediated Hippo signaling was validated at protein levels. Conclusions:Data suggest that NTX-301 exerts potent antileukemic activities superior to 5-AZA and synergizes with VEN in VEN-resistant and TP53-mutant AML, in part by suppressing DNMT1, inducing DNA damage responses and apoptosis through p53 signaling, and demethylating LATS1/2, thereby activating Hippo signaling.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML
Purpose:Hypomethylating agent (HMA) and the BCL-2 inhibitor venetoclax (VEN) combinations have evolved into first-line therapies for patients with acute myeloid leukemia (AML), yielding high response rates. However, most patients ultimately relapse, particularly those with TP53 mutations. We investigated mechanisms of action and therapeutic efficacy of NTX-301, a next-generation HMA. Experimental Design:Methods used include flow cytometry–based cell viability assays, Western blotting, reverse-phase protein arrays, RNA sequencing, Cytometry by Time-Of-Flight single-cell mass cytometry, and methylation profiling in various therapy-resistant AML models. Results:We demonstrate that NTX-301 exhibits superior efficacy compared with 5-azacytidine (5-AZA) in 5-AZA– or VEN-resistant AML. It synergizes with VEN in VEN- or VEN/HMA-resistant and TP53-mutant AML blasts and stem/progenitor cells (combination index <1). NTX-301 inhibits DNA methyltransferase 1 (DNMT1) and increases p73 and caspase 8 (CASP8)/activated CASP8 levels in TP53 wild-type and TP53-mutant AML and activates p53 signaling. It extends survival (≥45%) in both xenograft and patient-derived xenograft models. Methylation profiling revealed that NTX-301 is a more targeted HMA compared with 5-AZA, enabling suppression of functionally enriched genes/pathways. Pathway analysis of 954 commonly hypomethylated genes showed profoundly greater enrichment of Hippo signaling in NTX-301–treated compared with 5-AZA–treated cells and enrichment of insulin signaling, VEGF pathway, and cell cycle selectively in NTX-301– but not in 5-AZA–treated cells. NTX-301–mediated Hippo signaling was validated at protein levels. Conclusions:Data suggest that NTX-301 exerts potent antileukemic activities superior to 5-AZA and synergizes with VEN in VEN-resistant and TP53-mutant AML, in part by suppressing DNMT1, inducing DNA damage responses and apoptosis through p53 signaling, and demethylating LATS1/2, thereby activating Hippo signaling.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables1 from The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML
Supplementary Tables1 from The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables1 from The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML
Supplementary Tables1 from The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML
- 13 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4151-4165
The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53 -Mutant AML
Purpose: Hypomethylating agent (HMA) and the BCL-2 inhibitor venetoclax (VEN) combinations have evolved into first-line therapies for patients with acute myeloid leukemia (AML), yielding high response rates. However, most patients ultimately relapse, particularly those with TP53 mutations. We investigated mechanisms of action and therapeutic efficacy of NTX-301, a next-generation HMA. Experimental Design: Methods used include flow cytometry–based cell viability assays, Western blotting, reverse-phase protein arrays, RNA sequencing, Cytometry by Time-Of-Flight single-cell mass cytometry, and methylation profiling in various therapy-resistant AML models. Results: We demonstrate that NTX-301 exhibits superior efficacy compared with 5-azacytidine (5-AZA) in 5-AZA– or VEN-resistant AML. It synergizes with VEN in VEN- or VEN/HMA-resistant and TP53-mutant AML blasts and stem/progenitor cells (combination index <1). NTX-301 inhibits DNA methyltransferase 1 (DNMT1) and increases p73 and caspase 8 (CASP8)/activated CASP8 levels in TP53 wild-type and TP53-mutant AML and activates p53 signaling. It extends survival (≥45%) in both xenograft and patient-derived xenograft models. Methylation profiling revealed that NTX-301 is a more targeted HMA compared with 5-AZA, enabling suppression of functionally enriched genes/pathways. Pathway analysis of 954 commonly hypomethylated genes showed profoundly greater enrichment of Hippo signaling in NTX-301–treated compared with 5-AZA–treated cells and enrichment of insulin signaling, VEGF pathway, and cell cycle selectively in NTX-301– but not in 5-AZA–treated cells. NTX-301–mediated Hippo signaling was validated at protein levels. Conclusions: Data suggest that NTX-301 exerts potent antileukemic activities superior to 5-AZA and synergizes with VEN in VEN-resistant and TP53-mutant AML, in part by suppressing DNMT1, inducing DNA damage responses and apoptosis through p53 signaling, and demethylating LATS1/2, thereby activating Hippo signaling.
- 13 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4151-4165
The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53 -Mutant AML
Purpose: Hypomethylating agent (HMA) and the BCL-2 inhibitor venetoclax (VEN) combinations have evolved into first-line therapies for patients with acute myeloid leukemia (AML), yielding high response rates. However, most patients ultimately relapse, particularly those with TP53 mutations. We investigated mechanisms of action and therapeutic efficacy of NTX-301, a next-generation HMA. Experimental Design: Methods used include flow cytometry–based cell viability assays, Western blotting, reverse-phase protein arrays, RNA sequencing, Cytometry by Time-Of-Flight single-cell mass cytometry, and methylation profiling in various therapy-resistant AML models. Results: We demonstrate that NTX-301 exhibits superior efficacy compared with 5-azacytidine (5-AZA) in 5-AZA– or VEN-resistant AML. It synergizes with VEN in VEN- or VEN/HMA-resistant and TP53-mutant AML blasts and stem/progenitor cells (combination index <1). NTX-301 inhibits DNA methyltransferase 1 (DNMT1) and increases p73 and caspase 8 (CASP8)/activated CASP8 levels in TP53 wild-type and TP53-mutant AML and activates p53 signaling. It extends survival (≥45%) in both xenograft and patient-derived xenograft models. Methylation profiling revealed that NTX-301 is a more targeted HMA compared with 5-AZA, enabling suppression of functionally enriched genes/pathways. Pathway analysis of 954 commonly hypomethylated genes showed profoundly greater enrichment of Hippo signaling in NTX-301–treated compared with 5-AZA–treated cells and enrichment of insulin signaling, VEGF pathway, and cell cycle selectively in NTX-301– but not in 5-AZA–treated cells. NTX-301–mediated Hippo signaling was validated at protein levels. Conclusions: Data suggest that NTX-301 exerts potent antileukemic activities superior to 5-AZA and synergizes with VEN in VEN-resistant and TP53-mutant AML, in part by suppressing DNMT1, inducing DNA damage responses and apoptosis through p53 signaling, and demethylating LATS1/2, thereby activating Hippo signaling.
- Open Access
NanoCellAnnotator: Formalizing Expert Cell Type Annotation with Large Language Models
Motivation: Cell-type annotation in spatial transcriptomics is challenging due to sparse gene panels, spatial heterogeneity, and limited availability of tissue-matched reference atlases. Recent approaches have explored large language models (LLMs) for integrating biological knowledge during annotation, but unconstrained inference can produce biologically unsupported predictions and hallucinated cell types. In addition, many LLM-based pipelines rely on large cloud-hosted models that limit reproducibility and deployment in privacy-sensitive environments. Results: We introduce NanoCellAnnotator, a biologically constrained and confidence-aware framework for automated cell-type annotation in spatial transcriptomics. The framework de-couples spatial structure discovery, deterministic biological evidence construction, and language model-based semantic inference. Spatial clusters are identified using hybrid spatially regularized non-negative matrix factorization (hSNMF), after which cluster-level marker genes are abstracted into ontology-derived functional programs using Gene Ontology enrichment and GO-slim projection. A lightweight locally executable language model performs constrained label selection within a curated admissible label space derived from PanglaoDB and CellMarker. Annotation confidence is estimated independently using marker support strength and lineage separation, enabling ambiguous or heterogeneous clusters to be explicitly flagged. We evaluate NanoCellAnnotator on Xenium spatial transcriptomics data from intrahepatic cholangiocarci-noma and an independent breast cancer spatial transcriptomics dataset. The framework recovers canonical cell populations with high confidence while identifying heterogeneous or transitional spatial domains as ambiguous. Agreement with manual annotations was evaluated using accuracy and adjusted Rand index. Availability: Code available at https://github.com/ishtyaqmahmud/NanoCellAnnotator.
Open AccessNanoCellAnnotator: Formalizing Expert Cell Type Annotation with Large Language Models
Motivation: Cell-type annotation in spatial transcriptomics is challenging due to sparse gene panels, spatial heterogeneity, and limited availability of tissue-matched reference atlases. Recent approaches have explored large language models (LLMs) for integrating biological knowledge during annotation, but unconstrained inference can produce biologically unsupported predictions and hallucinated cell types. In addition, many LLM-based pipelines rely on large cloud-hosted models that limit reproducibility and deployment in privacy-sensitive environments. Results: We introduce NanoCellAnnotator, a biologically constrained and confidence-aware framework for automated cell-type annotation in spatial transcriptomics. The framework de-couples spatial structure discovery, deterministic biological evidence construction, and language model-based semantic inference. Spatial clusters are identified using hybrid spatially regularized non-negative matrix factorization (hSNMF), after which cluster-level marker genes are abstracted into ontology-derived functional programs using Gene Ontology enrichment and GO-slim projection. A lightweight locally executable language model performs constrained label selection within a curated admissible label space derived from PanglaoDB and CellMarker. Annotation confidence is estimated independently using marker support strength and lineage separation, enabling ambiguous or heterogeneous clusters to be explicitly flagged. We evaluate NanoCellAnnotator on Xenium spatial transcriptomics data from intrahepatic cholangiocarci-noma and an independent breast cancer spatial transcriptomics dataset. The framework recovers canonical cell populations with high confidence while identifying heterogeneous or transitional spatial domains as ambiguous. Agreement with manual annotations was evaluated using accuracy and adjusted Rand index. Availability: Code available at https://github.com/ishtyaqmahmud/NanoCellAnnotator.
- Open Access
Ambiguity-Aware Multi-Stage Cell-Type Annotation for Spatial Transcriptomics
Spatial transcriptomics enables characterization of cellular organization in intact tissue, but robust cell-type annotation remains challenging due to heterogeneous expression profiles, mixed populations, and transitional states. Existing methods often enforce a single label per cluster, obscuring biologically meaningful ambiguity and producing overconfident assignments. We propose an ambiguity-aware, multi-stage framework for spatial cell-type annotation. The method combines hybrid spatial–feature clustering with constrained language-model inference over curated label sets, and assigns confidence scores based on marker coverage, candidate separation, and entropy. Low-confidence clusters are selectively refined via local reclustering of ambiguous regions, while unresolved clusters are preserved as mixed rather than forcibly labeled. Applied to 10x Genomics Xenium spatial transcriptomics data from cholangiocarcinoma, the proposed refinement reduces cluster-level ambiguity from 16.1% to 2.27% and cell-level ambiguity from 18.4% to 0.86%, while improving confidence calibration. Spatial ablation confirms that topological integration resolves structural ambiguity over feature-only baselines, while constrained inference via a lightweight language model ensures scalable and biologically coherent annotations. These results highlight the importance of explicit ambiguity handling for reliable spatial annotation in heterogeneous tumors.
Open AccessAmbiguity-Aware Multi-Stage Cell-Type Annotation for Spatial Transcriptomics
Spatial transcriptomics enables characterization of cellular organization in intact tissue, but robust cell-type annotation remains challenging due to heterogeneous expression profiles, mixed populations, and transitional states. Existing methods often enforce a single label per cluster, obscuring biologically meaningful ambiguity and producing overconfident assignments. We propose an ambiguity-aware, multi-stage framework for spatial cell-type annotation. The method combines hybrid spatial–feature clustering with constrained language-model inference over curated label sets, and assigns confidence scores based on marker coverage, candidate separation, and entropy. Low-confidence clusters are selectively refined via local reclustering of ambiguous regions, while unresolved clusters are preserved as mixed rather than forcibly labeled. Applied to 10x Genomics Xenium spatial transcriptomics data from cholangiocarcinoma, the proposed refinement reduces cluster-level ambiguity from 16.1% to 2.27% and cell-level ambiguity from 18.4% to 0.86%, while improving confidence calibration. Spatial ablation confirms that topological integration resolves structural ambiguity over feature-only baselines, while constrained inference via a lightweight language model ensures scalable and biologically coherent annotations. These results highlight the importance of explicit ambiguity handling for reliable spatial annotation in heterogeneous tumors.
- Open Access
Spatially Anchored Regulatory State Inference in Melanoma
Spatial transcriptomics (ST) captures gene expression within tissue architecture but lacks direct regulatory information, while single-cell multiome assays profile transcriptional and chromatin states without spatial context. We present a framework for spatially anchored regulatory inference that integrates Visium ST with single-cell multiome data to infer spatially resolved regulatory programs. Building upon GraphST, we introduce spatially regularized cell-to-spot mapping and propagate chromatin accessibility and transcription factor motif activity into tissue space. Regulatory analysis is performed at the spatial domain level via joint differential expression and accessibility testing, along with quantitative concordance assessment. Applied to melanoma tissue sections, the framework reveals spatially localized regulatory programs and shows that assignment strategy substantially affects downstream regulatory stability. This modular approach enables interpretable gene-, peak-, and transcription factor–level outputs for multimodal spatial analysis.
Open AccessSpatially Anchored Regulatory State Inference in Melanoma
Spatial transcriptomics (ST) captures gene expression within tissue architecture but lacks direct regulatory information, while single-cell multiome assays profile transcriptional and chromatin states without spatial context. We present a framework for spatially anchored regulatory inference that integrates Visium ST with single-cell multiome data to infer spatially resolved regulatory programs. Building upon GraphST, we introduce spatially regularized cell-to-spot mapping and propagate chromatin accessibility and transcription factor motif activity into tissue space. Regulatory analysis is performed at the spatial domain level via joint differential expression and accessibility testing, along with quantitative concordance assessment. Applied to melanoma tissue sections, the framework reveals spatially localized regulatory programs and shows that assignment strategy substantially affects downstream regulatory stability. This modular approach enables interpretable gene-, peak-, and transcription factor–level outputs for multimodal spatial analysis.
- Open Access
- 12 October 2025
- Published by Association for Computing Machinery (ACM)
- p. 1-6
Benchmarking Dimensionality Reduction Techniques for Spatial Transcriptomics
- 12 October 2025
- Published by Association for Computing Machinery (ACM)
- p. 1-6
Open AccessBenchmarking Dimensionality Reduction Techniques for Spatial Transcriptomics